Response Evaluation Criteria in Grade 1/2 Neuroendocrine Tumors (RECIN).

Aggarwal P, Satapathy S, Chandekar KR, Sood A

DOI: 10.1053/j.semnuclmed.2025.11.009
Published: 2026 Jan
Container: Seminars in nuclear medicine
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1053/j.semnuclmed.2025.11.009,
  title = {Response Evaluation Criteria in Grade 1/2 Neuroendocrine Tumors (RECIN).},
  author = {Aggarwal P and Satapathy S and Chandekar KR and Sood A},
  year = {2026},
  journal = {Seminars in nuclear medicine},
  doi = {10.1053/j.semnuclmed.2025.11.009},
  url = {https://doi.org/10.1053/j.semnuclmed.2025.11.009}
}

RIS

TY  - JOUR
TI  - Response Evaluation Criteria in Grade 1/2 Neuroendocrine Tumors (RECIN).
AU  - Aggarwal P
AU  - Satapathy S
AU  - Chandekar KR
AU  - Sood A
PY  - 2026
JO  - Seminars in nuclear medicine
DO  - 10.1053/j.semnuclmed.2025.11.009
UR  - https://doi.org/10.1053/j.semnuclmed.2025.11.009
ER  -

APA

P, A., S, S., KR, C., & A, S. (2026). Response Evaluation Criteria in Grade 1/2 Neuroendocrine Tumors (RECIN).. Seminars in nuclear medicine. https://doi.org/10.1053/j.semnuclmed.2025.11.009

Source records

pubmed · retrieved 2026-11-10T13:44:04.746Z